• Japanese
  • Korean
  • Chinese
Cover Image

Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Abstract

Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, "Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Gastrointestinal Stromal Tumors (GIST) Therapeutics market. The report identifies the key trends shaping and driving the global Gastrointestinal Stromal Tumors (GIST) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Gastrointestinal Stromal Tumors (GIST) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Gastrointestinal Stromal Tumors (GIST) Therapeutics market. Its scope includes -

  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Gastrointestinal Stromal Tumors (GIST) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Gastrointestinal Stromal Tumors (GIST) Therapeutics market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Gastrointestinal Stromal Tumors (GIST) Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Gastrointestinal Stromal Tumors (GIST) Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Gastrointestinal Stromal Tumors (GIST) Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Gastrointestinal Stromal Tumors (GIST) Therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What's the next big thing in the global Gastrointestinal Stromal Tumors (GIST) Therapeutics market landscape? - Identify, understand and capitalize.

TOC

1 Table of Contents

1 Table of Contents 3

  • 1.1 List of Tables 5
  • 1.2 List of Figures 6

2 Gastrointestinal Stromal Tumors Therapeutics - Introduction 7

  • 2.1 Overview 7
  • 2.2 Epidemiology 8
  • 2.3 Symptoms 9
  • 2.4 Etiology 9
  • 2.5 Staging of Gastrointestinal Stromal Tumors 10
  • 2.6 Diagnosis of Gastrointestinal Stromal Tumors 10
    • 2.6.1 Computed Tomography Scan 10
    • 2.6.2 Barium Swallow 11
    • 2.6.3 Magnetic Resonance Imaging or Positron Emission Tomography 11
    • 2.6.4 Mutational Analysis 11
  • 2.7 Treatment of Gastrointestinal Stromal Tumors 11
    • 2.7.1 Surgery 11
    • 2.7.2 Radiation Therapy 12
    • 2.7.3 Chemotherapy 12
    • 2.7.4 Targeted Therapy 12
  • 2.8 Treatment and Management Pattern 13
  • 2.9 Referral Pathway 14
  • 2.10 GlobalData Pipeline Report Guidance 15

3 Gastrointestinal Stromal Tumors Therapeutics - Market Characterization 16

  • 3.1 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006-2011) - Global 16
  • 3.2 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011-2019) - Global 18
  • 3.3 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006-2011) - The US 20
  • 3.4 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011-2019) - The US 21
  • 3.5 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006-2011) - The UK 22
  • 3.6 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011-2019) - The UK 23
  • 3.7 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006-2011) - France 24
  • 3.8 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011-2019) - France 25
  • 3.9 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006-2011) - Germany 26
  • 3.10 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011-2019) - Germany 27
  • 3.11 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006-2011) - Italy 28
  • 3.12 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011-2019) - Italy 29
  • 3.13 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006-2011) - Spain 30
  • 3.14 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011-2019) - Spain 31
  • 3.15 Gastrointestinal Stromal Tumors Market Size (2006-2011) - Japan 32
  • 3.16 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011-2019) - Japan 33
  • 3.17 Drivers and Barriers for the Gastrointestinal Stromal Tumors Market 34
    • 3.17.1 Drivers for the Gastrointestinal Stromal Tumors Market 34
    • 3.17.2 Barriers for the Gastrointestinal Stromal Tumors Therapeutics Market 35
  • 3.18 Opportunity and Unmet Need 36
  • 3.19 Key Takeaway 37

4 Gastrointestinal Stromal Tumors Therapeutics - Competitive Assessment 38

  • 4.1 Overview 38
  • 4.2 Strategic Competitor Assessment 38
  • 4.3 Marketed Product Profile 39
    • 4.3.1 Gleevec (imatinib mesylate) 39
    • 4.3.2 Sutent (sunitinib malate) 41
  • 4.4 Key Takeaway 43

5 Gastrointestinal Stromal Tumors Therapeutics - Pipeline Assessment 44

  • 5.1 Overview 44
  • 5.2 Strategic Pipeline Assessment 44
  • 5.3 Gastrointestinal Stromal Tumors Therapeutics Pipeline Analysis - Pipeline by Clinical Phase of Development 45
    • 5.3.1 Gastrointestinal Stromal Tumors Therapeutics - Phase III Clinical Pipeline 45
    • 5.3.2 Gastrointestinal Stromal Tumors Therapeutics - Phase II/III Clinical Pipeline 46
    • 5.3.3 Gastrointestinal Stromal Tumors Therapeutics - Phase II Clinical Pipeline 46
    • 5.3.4 Gastrointestinal Stromal Tumors Therapeutics - Phase I/II Clinical Pipeline 46
    • 5.3.5 Gastrointestinal Stromal Tumors Therapeutics - Phase I Clinical Pipeline 47
    • 5.3.6 Gastrointestinal Stromal Tumors Therapeutics - Preclinical Phase 47
  • 5.4 Gastrointestinal Stromal Tumors Therapeutics Pipeline Analysis - Pipeline by Mechanism of Action 48
  • 5.5 Gastrointestinal Stromal Tumors Technology Trends Analytical Framework 49
  • 5.6 Molecule Profile for Late-stage Molecules under Clinical Development 50
    • 5.6.1 Masitinib 50
    • 5.6.2 Nexavar (sorafenib) 51
    • 5.6.3 Regorafenib (BAY 73-4506) 52
    • 5.6.4 Tasigna (nilotinib) 53
  • 5.7 Key Takeaway 53

6 Gastrointestinal Stromal Tumors Therapeutics - Clinical Trial Mapping 54

  • 6.1 Clinical Trial Mapping by Country (The US, EU5 and Japan) 54
  • 6.2 Clinical Trial Mapping by Phase 55
  • 6.3 Clinical Trial Mapping by Trial Status 56
  • 6.4 Clinical Trial Mapping Overall Sponsors 57
  • 6.5 Clinical Trial Mapping by Prominent Sponsors 58
  • 6.6 Clinical Trial Mapping by Companies 59

7 Gastrointestinal Stromal Tumors Therapeutics - Strategic Assessment 60

  • 7.1 Gastrointestinal Stromal Tumors Therapeutics: Implications for Future Market Competition 60

8 Gastrointestinal Stromal Tumors Therapeutics - Future Players in the Market 62

  • 8.1 Introduction 62
  • 8.2 Company Profiles 62
    • 8.2.1 Novartis AG 62
    • 8.2.2 AB Science 63
    • 8.2.3 Bayer AG 64
  • 8.3 Gastrointestinal Stromal Tumors Therapeutics Market - Other Future Players 65

9 Gastrointestinal Stromal Tumors Therapeutics - Licensing and Partnership Deals 67

10 Gastrointestinal Stromal Tumors Therapeutics - Appendix 68

  • 10.1 Definitions 68
  • 10.2 Acronyms 68
  • 10.3 Bibliography 69
  • 10.4 Research Methodology 71
    • 10.4.1 Coverage 71
    • 10.4.2 Secondary Research 72
    • 10.4.3 Forecasting 72
    • 10.4.4 Primary Research 74
    • 10.4.5 Expert Panel Validation 75
  • 10.5 Contact Us 75
  • 10.6 Disclaimer 75

List of Tables

1.1 List of Tables

  • Table 1: Historical Prevalence of Gastrointestinal Stromal Tumors in Seven Major Markets, 2006-2011 (approximate) 8
  • Table 2: Forecast Prevalence of Gastrointestinal Stromal Tumors in Seven Major Markets, 2011-2019 (approximate) 9
  • Table 3: Occurrence Rate of Symptoms of Gastrointestinal Stromal Tumors, 2010 9
  • Table 4: TNM Staging, Gastrointestinal Stromal Tumors, 2011 10
  • Table 5: Gastrointestinal Stromal Tumors Therapeutics Market, Global, Revenue ($m), 2006-2011 16
  • Table 6: Gastrointestinal Stromal Tumors Therapeutics Market, Global, Forecast ($m), 2011-2019 18
  • Table 7: Gastrointestinal Stromal Tumors Therapeutics Market, The US, Revenue ($m), 2006-2011 20
  • Table 8: Gastrointestinal Stromal Tumors Therapeutics Market, The US, Forecast ($m), 2011-2019 21
  • Table 9: Gastrointestinal Stromal Tumors Therapeutics Market, The UK, Revenue ($m), 2006-2011 22
  • Table 10: Gastrointestinal Stromal Tumors Therapeutics Market, The UK, Forecast ($m), 2011-2019 23
  • Table 11: Gastrointestinal Stromal Tumors Therapeutics Market, France, Revenue ($m), 2006-2011 24
  • Table 12: Gastrointestinal Stromal Tumors Therapeutics Market, France, Forecast ($m), 2011-2019 25
  • Table 13: Gastrointestinal Stromal Tumors Therapeutics Market, Germany, Revenue ($m), 2006-2011 26
  • Table 14: Gastrointestinal Stromal Tumors Therapeutics Market, Germany, Forecast ($m), 2011-2019 27
  • Table 15: Gastrointestinal Stromal Tumors Therapeutics Market, Italy, Revenue ($m), 2006-2011 28
  • Table 16: Gastrointestinal Stromal Tumors Therapeutics Market, Italy, Forecast ($m), 2011-2019 29
  • Table 17: Gastrointestinal Stromal Tumors Therapeutics Market, Spain, Revenue ($m), 2006-2011 30
  • Table 18: Gastrointestinal Stromal Tumors Therapeutics Market, Spain, Forecast ($m), 2011-2019 31
  • Table 19: Gastrointestinal Stromal Tumors Therapeutics Market, Japan, Revenue ($m), 2006-2011 32
  • Table 20: Gastrointestinal Stromal Tumors Therapeutics Market, Japan, Forecast ($m), 2011-2019 33
  • Table 21: Gastrointestinal Stromal Tumors Efficacy Results, Sutent 42
  • Table 22: Gastrointestinal Stromal Tumors Therapeutics - Phase III Pipeline 45
  • Table 23: Gastrointestinal Stromal Tumors Therapeutics - Phase II/III Pipeline 46
  • Table 24: Gastrointestinal Stromal Tumors Therapeutics - Phase II Pipeline 46
  • Table 25: Gastrointestinal Stromal Tumors Therapeutics - Phase I/II Pipeline 46
  • Table 26: Gastrointestinal Stromal Tumors Therapeutics - Phase I Pipeline 47
  • Table 27: Gastrointestinal Stromal Tumors Therapeutics - Preclinical Phase 47
  • Table 28: Nexavar Phase II Trial - Summary of Results, 2011 52
  • Table 29: Gastrointestinal Stromal Tumors Therapeutics - Clinical Trials by Country, 2012 54
  • Table 30: Gastrointestinal Stromal Tumors Therapeutics - Clinical Trials by Phase, 2012 55
  • Table 31: Gastrointestinal Stromal Tumors Therapeutics - Clinical Trials by Status, 2012 56
  • Table 32: Gastrointestinal Stromal Tumors Therapeutics, Overall Sponsors, 2012 57
  • Table 33: Gastrointestinal Stromal Tumors Therapeutics - Prominent Sponsors, 2012 58
  • Table 34: Gastrointestinal Stromal Tumors Therapeutics - Companies, 2012 59
  • Table 35: Gastrointestinal Stromal Tumors Pipeline, Novartis AG 63
  • Table 36: Gastrointestinal Stromal Tumors Pipeline, AB Science 64
  • Table 37: Gastrointestinal Stromal Tumors Pipeline, Bayer AG 64
  • Table 38: Gastrointestinal Stromal Tumors Therapeutics, Other Future Players 65
  • Table 39: Gastrointestinal Stromal Tumors Therapeutics, Global, Deals, 2012 67

List of Figures

1.2 List of Figures

  • Figure 1: Distribution of Gastrointestinal Stromal Tumors 7
  • Figure 2: Patient Share of Gastrointestinal Stromal Tumors in the Seven Major Markets, 2011 8
  • Figure 3: Gastrointestinal Stromal Tumors Therapeutics - Treatment Algorithm 13
  • Figure 4: Referral Pathway for Gastrointestinal Stromal Tumors 14
  • Figure 5: Gastrointestinal Stromal Tumors Therapeutics Market, Global, Revenue ($m), 2006-2011 16
  • Figure 6: Gastrointestinal Stromal Tumors Therapeutics, Global Market Share ($m), 2011 17
  • Figure 7: Gastrointestinal Stromal Tumors Therapeutics Market, Global, Forecast ($m), 2011-2019 18
  • Figure 8: Gastrointestinal Stromal Tumors Therapeutics, Global Market Share ($m), 2019 19
  • Figure 9: Gastrointestinal Stromal Tumors Therapeutics Market, The US, Revenue ($m), 2006-2011 20
  • Figure 10: Gastrointestinal Stromal Tumors Therapeutics Market, The US, Forecast ($m), 2011-2019 21
  • Figure 11: Gastrointestinal Stromal Tumors Therapeutics Market, The UK, Revenue ($m), 2006-2011 22
  • Figure 12: Gastrointestinal Stromal Tumors Therapeutics Market, The UK, Forecast ($m), 2011-2019 23
  • Figure 13: Gastrointestinal Stromal Tumors Therapeutics Market, France, Revenue ($m), 2006-2011 24
  • Figure 14: Gastrointestinal Stromal Tumors Therapeutics Market, France, Forecast ($m), 2011-2019 25
  • Figure 15: Gastrointestinal Stromal Tumors Therapeutics Market, Germany, Revenue ($m), 2006-2011 26
  • Figure 16: Gastrointestinal Stromal Tumors Therapeutics Market, Germany, Forecast ($m), 2011-2019 27
  • Figure 17: Gastrointestinal Stromal Tumors Therapeutics Market, Italy, Revenue ($m), 2006-2011 28
  • Figure 18: Gastrointestinal Stromal Tumors Therapeutics Market, Italy, Forecast ($m), 2011-2019 29
  • Figure 19: Gastrointestinal Stromal Tumors Therapeutics Market, Spain, Revenue ($m), 2006-2011 30
  • Figure 20: Gastrointestinal Stromal Tumors Therapeutics Market, Spain, Forecast ($m), 2011-2019 31
  • Figure 21: Gastrointestinal Stromal Tumors Therapeutics Market, Japan, Revenue ($m), 2006-2011 32
  • Figure 22: Gastrointestinal Stromal Tumors Therapeutics Market, Japan, Forecast ($m), 2011-2019 33
  • Figure 23: Drivers and Barriers for Gastrointestinal Stromal Tumor Therapeutics, 2012 35
  • Figure 24: Opportunity and Unmet Need in the Primary (Resectable) Gastrointestinal Stromal Tumors Therapeutics Market, 2012 36
  • Figure 25: Opportunity and Unmet Need in the Metastatic/Unresectable Gastrointestinal Stromal Tumors Therapeutics Market, 2012 37
  • Figure 26: Gastrointestinal Stromal Tumors Therapeutics Market - Strategic Competitor Assessment, 2012 39
  • Figure 27: Gleevec Phase III Trial Results - Progression-free Survival 40
  • Figure 28: Gleevec Phase III Trial Results - Overall Response Rate 41
  • Figure 29: Sutent - Time to Tumor Progression in Gastrointestinal Stromal Tumor Patients 42
  • Figure 30: Gastrointestinal Stromal Tumors Therapeutics - Pipeline by Phase of Development, 2012 45
  • Figure 31: Gastrointestinal Stromal Tumors Therapeutics - Clinical Pipeline by Mechanism of Action, 2012 48
  • Figure 32: Technology Trends Analytical Framework of the Gastrointestinal Stromal Tumors Pipeline, 2012 49
  • Figure 33: Technology Trends Analytical Framework of the Gastrointestinal Stromal Tumors Pipeline, 2012 50
  • Figure 34: Gastrointestinal Stromal Tumors Therapeutics - Clinical Trials by Country, 2012 54
  • Figure 35: Gastrointestinal Stromal Tumors Therapeutics - Clinical Trials by Phase, 2012 55
  • Figure 36: Gastrointestinal Stromal Tumors Therapeutics - Clinical Trials by Status, 2012 56
  • Figure 37: Gastrointestinal Stromal Tumors Therapeutics - Overall Sponsors, 2012 57
  • Figure 38: Gastrointestinal Stromal Tumors Therapeutics - Prominent Sponsors, 2012 58
  • Figure 39: Gastrointestinal Stromal Tumors Therapeutics - Companies, 2012 59
  • Figure 40: Implications for Future Market Competition in the Gastrointestinal Stromal Tumors Therapeutics Market, 2012 60
  • Figure 41: Gastrointestinal Stromal Tumors Therapeutics - Future Players, 2012 62
  • Figure 42: GlobalData Market Forecasting Model 74
Show More
Pricing